RxDoctor Payments Data

Kathy Baglan, MD

Radiation Oncology · Saint Louis, MONPI 1538122163

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Myriad Genetic Laboratories, Inc. at 38.2% of the total. Reporting peaked in 2023 at $809 and has fallen 54.3% since, to $370 in 2025.

$1,577in general payments, 2019–2025

Across 42 payments — averaging $37.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Myriad Genetic Laboratories, Inc.$603
  • Novartis$149
  • Boston Scientific$138
  • Regeneron Healthcare Solutions, Inc.$123
  • Sumitomo Pharma America, Inc.$103
  • Elekta, Inc.$93
  • plus $368 from 11 others

What the payments were for

  • Food & beverage$1,577100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,577 in reported general payments places this provider in the 60th percentile of 123 radiation oncology providers in Missouri.

See all radiation oncology providers in Missouri

Medicare billing

Part B allowed, 2024
$104,728
Medicare patients
222
Services billed
1,264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamsulosin Hcl165$1,227
Dexamethasone53$236

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →